The microbiome in bronchiectasis

Hollian Richardson, Alison J. Dicker, Heather Barclay, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journalArticle

3 Downloads (Pure)

Abstract

Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by Pseudomonas, Haemophilus and Streptococcus, while exhibiting intraindividual stability and large interindividual variability. Pseudomonas- and Haemophilus-dominated microbiomes have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are limited in size and do not fully represent all clinically observed disease subtypes. Further research is required to understand the microbiomes role in bronchiectasis disease progression. This review discusses recent developments and future perspectives on the lung microbiome in bronchiectasis.

Original languageEnglish
Article number190048
Pages (from-to)1-10
Number of pages10
JournalEuropean Respiratory Review
Volume28
Issue number153
Early online date4 Sep 2019
DOIs
Publication statusE-pub ahead of print - 4 Sep 2019

Fingerprint

Bronchiectasis
Microbiota
Disease Progression
Haemophilus
Pseudomonas
Lung
Streptococcus
Bacteria
Research

Cite this

@article{86488d80d82f4cf984f2481a34230194,
title = "The microbiome in bronchiectasis",
abstract = "Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by Pseudomonas, Haemophilus and Streptococcus, while exhibiting intraindividual stability and large interindividual variability. Pseudomonas- and Haemophilus-dominated microbiomes have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are limited in size and do not fully represent all clinically observed disease subtypes. Further research is required to understand the microbiomes role in bronchiectasis disease progression. This review discusses recent developments and future perspectives on the lung microbiome in bronchiectasis.",
author = "Hollian Richardson and Dicker, {Alison J.} and Heather Barclay and Chalmers, {James D.}",
note = "Copyright {\circledC} ERS 2019.",
year = "2019",
month = "9",
day = "4",
doi = "10.1183/16000617.0048-2019",
language = "English",
volume = "28",
pages = "1--10",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "153",

}

The microbiome in bronchiectasis. / Richardson, Hollian; Dicker, Alison J.; Barclay, Heather; Chalmers, James D. (Lead / Corresponding author).

In: European Respiratory Review, Vol. 28, No. 153, 190048, 30.09.2019, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The microbiome in bronchiectasis

AU - Richardson, Hollian

AU - Dicker, Alison J.

AU - Barclay, Heather

AU - Chalmers, James D.

N1 - Copyright © ERS 2019.

PY - 2019/9/4

Y1 - 2019/9/4

N2 - Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by Pseudomonas, Haemophilus and Streptococcus, while exhibiting intraindividual stability and large interindividual variability. Pseudomonas- and Haemophilus-dominated microbiomes have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are limited in size and do not fully represent all clinically observed disease subtypes. Further research is required to understand the microbiomes role in bronchiectasis disease progression. This review discusses recent developments and future perspectives on the lung microbiome in bronchiectasis.

AB - Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by Pseudomonas, Haemophilus and Streptococcus, while exhibiting intraindividual stability and large interindividual variability. Pseudomonas- and Haemophilus-dominated microbiomes have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are limited in size and do not fully represent all clinically observed disease subtypes. Further research is required to understand the microbiomes role in bronchiectasis disease progression. This review discusses recent developments and future perspectives on the lung microbiome in bronchiectasis.

U2 - 10.1183/16000617.0048-2019

DO - 10.1183/16000617.0048-2019

M3 - Article

VL - 28

SP - 1

EP - 10

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 153

M1 - 190048

ER -